# 🧬 CGGA WESeq Cohort - APOE Genotyping Analysis

## Executive Summary

**Project:** Comprehensive APOE genotyping of CGGA WESeq cohort  
**Date Started:** October 26, 2025  
**Total Patients:** 26 (HRR024685 - HRR024710)  
**Analysis Type:** Whole Genome Sequencing → APOE ε2/ε3/ε4 Genotyping  
**Status:** ⏳ **IN PROGRESS** (Sample 2/26 processing)

---

## 📊 Cohort Overview

### Patient Samples:
- **Source:** CGGA (Chinese Glioma Genome Atlas) WESeq
- **Data Type:** Paired-end whole genome sequencing (FASTQ)
- **Sample Size:** 26 patients
- **Sample IDs:** HRR024685, HRR024686, HRR024687... HRR024710
- **Sequencing Platform:** Illumina (inferred from data structure)

### Analysis Objective:
Determine APOE genotype for each patient to assess:
1. Individual Alzheimer's disease genetic risk
2. Cohort-level genotype distribution
3. Population genetics insights
4. Research applications

---

## 🔬 Scientific Background

### APOE Gene & Alzheimer's Disease:
- **Gene:** Apolipoprotein E (APOE)
- **Location:** Chromosome 19:45,409,039-45,412,650 (GRCh37/hg19)
- **Function:** Lipid transport, cholesterol metabolism, brain health
- **Clinical Significance:** Strongest genetic risk factor for late-onset Alzheimer's disease

### Three Common Alleles:
1. **ε2** (protective) - ~8% frequency
2. **ε3** (neutral) - ~78% frequency  
3. **ε4** (risk factor) - ~14% frequency

### Defined by Two SNPs:
1. **rs429358** (chr19:45,411,941)
   - C→T change (Cys→Arg at position 112)
2. **rs7412** (chr19:45,412,079)
   - C→T change (Arg→Cys at position 158)

### Six Possible Genotypes:

| Genotype | rs429358 | rs7412 | AD Risk | Population Frequency |
|----------|----------|--------|---------|---------------------|
| ε2/ε2 | C/C | T/T | 0.5x (protective) | <1% |
| ε2/ε3 | C/C | C/T | 0.6x (protective) | ~10% |
| ε2/ε4 | C/T | C/T | 2-3x (moderate) | ~2% |
| ε3/ε3 | C/C | C/C | 1x (average) | ~60% |
| ε3/ε4 | C/T | C/C | 3x (increased) | ~20% |
| ε4/ε4 | T/T | C/C | 8-12x (high risk) | ~2% |

---

## 🔄 Analysis Pipeline

### Workflow (Per Sample):

```
FASTQ Files (Raw Reads)
    ↓
[1] Quality Control (optional FastQC)
    ↓
[2] Alignment to Reference Genome (BWA-MEM)
    • Reference: GRCh37/hg19
    • Time: ~20-30 minutes
    ↓
[3] BAM Sorting & Indexing (SAMtools)
    • Time: ~5-10 minutes
    ↓
[4] Extract APOE Region (SAMtools)
    • Region: chr19:45,409,039-45,412,650
    • Time: ~1-2 minutes
    ↓
[5] Coverage Calculation
    • Overall APOE coverage
    • Specific coverage at rs429358 and rs7412
    ↓
[6] Genotype Calling
    • Direct read inspection at key SNPs
    • Variant calling (BCFtools/SAMtools)
    ↓
[7] APOE Genotype Determination
    • Classify as ε2/ε3/ε4
    • Risk assessment
    ↓
[8] Individual Report Generation
```

**Total Time:** ~30-45 minutes per sample  
**For 26 Samples:** ~11-18 hours total

---

## 📁 Data Structure

### Input Data Location:
```
E:\CGGA WESeq\
├── HRR024685/
│   ├── HRR024685_f1.fq.gz    # Forward reads
│   ├── HRR024685_r2.fq.gz    # Reverse reads
│   └── HRR024685.sra          # Original SRA
├── HRR024686/
│   ├── HRR024686_f1.fq.gz
│   └── HRR024686_r2.fq.gz
└── ... (24 more samples)
```

### Output Data Structure:
```
D:\APOE\batch_analysis\
├── logs/
│   ├── HRR024685.log
│   ├── HRR024686.log
│   └── ... (one per sample)
│
├── results/
│   ├── HRR024685_summary.txt
│   ├── HRR024686_summary.txt
│   └── ... (genotype summaries)
│
├── HRR024685/
│   └── alignment/
│       ├── *.sorted.bam       # Full genome alignment
│       └── *.apoe.bam         # APOE region only
│
├── HRR024686/
│   └── ... (same structure)
│
└── summary/
    └── BATCH_SUMMARY_*.txt    # Final cohort report
```

---

## 📊 Expected Results

### For Each Patient (26 Individual Reports):

```
================================================================================
APOE GENOTYPING REPORT - Patient HRR######
================================================================================

Sample ID: HRR######
Analysis Date: 2025-10-26
Reference: GRCh37/hg19

--------------------------------------------------------------------------------
COVERAGE METRICS
--------------------------------------------------------------------------------

APOE Region (chr19:45409039-45412650):
  Average Coverage: XX.Xx
  
Key SNP Positions:
  rs429358 (chr19:45411941): XXx coverage
  rs7412 (chr19:45412079): XXx coverage

--------------------------------------------------------------------------------
GENOTYPE DATA
--------------------------------------------------------------------------------

rs429358: X/X (Cys/Arg at position 112)
rs7412: X/X (Arg/Cys at position 158)

--------------------------------------------------------------------------------
APOE GENOTYPE
--------------------------------------------------------------------------------

APOE Genotype: ε?/ε?

Allele 1: ε?
Allele 2: ε?

--------------------------------------------------------------------------------
ALZHEIMER'S DISEASE RISK ASSESSMENT
--------------------------------------------------------------------------------

Risk Category: [REDUCED/AVERAGE/INCREASED/HIGH]
Relative Risk: [X]x compared to population average
Population Frequency: [X]% have this genotype

Clinical Interpretation:
[Detailed interpretation based on genotype]

Important Notes:
- APOE is ONE of many risk factors
- Lifestyle and environment are crucial
- This is for research purposes only
- Consult genetic counselor for clinical decisions
```

### Cohort Summary Report:

```
================================================================================
CGGA WESeq COHORT - APOE GENOTYPING SUMMARY
================================================================================

Analysis Date: 2025-10-26
Total Samples: 26
Successful: XX
Failed: XX

--------------------------------------------------------------------------------
GENOTYPE DISTRIBUTION
--------------------------------------------------------------------------------

ε2/ε2: X patients (XX.X%)  [Expected: <1%]
ε2/ε3: X patients (XX.X%)  [Expected: ~10%]
ε2/ε4: X patients (XX.X%)  [Expected: ~2%]
ε3/ε3: X patients (XX.X%)  [Expected: ~60%]
ε3/ε4: X patients (XX.X%)  [Expected: ~20%]
ε4/ε4: X patients (XX.X%)  [Expected: ~2%]

--------------------------------------------------------------------------------
ALLELE FREQUENCIES
--------------------------------------------------------------------------------

ε2 allele: XX.X%  [Expected: ~8%]
ε3 allele: XX.X%  [Expected: ~78%]
ε4 allele: XX.X%  [Expected: ~14%]

--------------------------------------------------------------------------------
RISK STRATIFICATION
--------------------------------------------------------------------------------

Reduced Risk (ε2 carriers): X patients (XX.X%)
Average Risk (ε3/ε3): X patients (XX.X%)
Increased Risk (ε4 carriers): X patients (XX.X%)
  - Moderate Risk (ε3/ε4): X patients
  - High Risk (ε4/ε4): X patients

--------------------------------------------------------------------------------
QUALITY METRICS
--------------------------------------------------------------------------------

Average APOE Coverage: XX.Xx
Coverage at rs429358: XX.Xx
Coverage at rs7412: XX.Xx

High Quality Samples (>20x coverage): XX/26
Adequate Quality (10-20x coverage): XX/26
Low Quality (<10x coverage): XX/26

--------------------------------------------------------------------------------
STATISTICAL ANALYSIS
--------------------------------------------------------------------------------

Chi-square test vs. expected frequencies: p = X.XXX
Hardy-Weinberg equilibrium: p = X.XXX

Deviations from expected frequencies:
[Analysis of any significant deviations]

--------------------------------------------------------------------------------
RESEARCH IMPLICATIONS
--------------------------------------------------------------------------------

[Population-specific insights]
[Comparison with other cohorts]
[Clinical/research recommendations]
```

---

## 🎯 Clinical & Research Applications

### Individual Patient Benefits:
1. **Personalized Risk Assessment** - Understand genetic Alzheimer's risk
2. **Informed Decision Making** - Lifestyle modifications, monitoring
3. **Family Planning** - Genetic counseling considerations
4. **Research Participation** - Eligibility for prevention trials

### Cohort-Level Insights:
1. **Population Genetics** - APOE frequency in this cohort
2. **Risk Distribution** - Proportion at various risk levels
3. **Research Stratification** - Group patients by genetic risk
4. **Biomarker Studies** - Correlate genotype with other measures

### Potential Research Questions:
- Does APOE genotype correlate with glioma characteristics?
- Are there population-specific APOE frequencies?
- How does APOE distribution compare to reference populations?
- Can we identify gene-gene or gene-environment interactions?

---

## 📈 Quality Assurance

### Pipeline Validation:
- ✅ Reference genome: GRCh37/hg19 (1000 Genomes standard)
- ✅ Alignment tool: BWA-MEM (gold standard)
- ✅ Variant calling: SAMtools/BCFtools (validated)
- ✅ Known SNP positions: rs429358, rs7412 (well-established)

### Quality Metrics Tracked:
- Sequencing coverage at APOE locus
- Mapping quality scores
- Read agreement at key SNPs
- PCR duplicate rates
- Alignment statistics

### Acceptance Criteria:
- **Minimum coverage:** >8x at both SNP positions
- **Mapping quality:** MQ ≥30
- **Read agreement:** >80% for genotype call
- **No ambiguous calls:** Clear homozygous or heterozygous

---

## ⏱️ Timeline

**Started:** October 26, 2025, 13:34  
**Current Status:** Sample 2/26 (HRR024686 aligning)  
**Expected Completion:** October 27, 2025, ~7-8 AM  
**Total Runtime:** ~11-18 hours

### Milestones:
- ✅ Pipeline setup complete
- ⏳ Batch processing in progress (Sample 2/26)
- ⏳ First sample completion (~14:00-14:20)
- ⏳ Halfway point (~12 samples, ~6-9 hours)
- ⏳ All samples processed (~tomorrow morning)
- ⏳ Final cohort report generated
- ⏳ Statistical analysis complete

---

## 🔍 Monitoring & Access

### Live Monitoring:
```bash
# View progress
tail -f /mnt/d/APOE/batch_analysis.log

# Interactive monitor
bash /mnt/d/APOE/monitor_batch.sh

# Check completion count
ls /mnt/d/APOE/batch_analysis/results/*.txt | wc -l
```

### Access Results:
- **Individual reports:** `D:\APOE\batch_analysis\results\`
- **Cohort summary:** `D:\APOE\batch_analysis\summary\`
- **Full alignments:** `D:\APOE\batch_analysis\<SAMPLE_ID>\alignment\`
- **Logs:** `D:\APOE\batch_analysis\logs\`

---

## 📚 Documentation

- **This Overview:** `COHORT_ANALYSIS_OVERVIEW.md`
- **Live Progress:** `BATCH_PROGRESS.md`
- **Pipeline Script:** `batch_apoe_pipeline.sh`
- **Monitor Script:** `monitor_batch.sh`
- **Status Dashboard:** `BATCH_ANALYSIS_STATUS.md`

---

## ⚠️ Important Disclaimers

1. **Research Use Only** - Not for clinical diagnosis
2. **Genetic Counseling** - Recommend professional interpretation
3. **Risk is Probabilistic** - Not deterministic
4. **Multiple Factors** - APOE is one of many factors
5. **Lifestyle Matters** - Modifiable risk factors are crucial
6. **Privacy** - Handle genetic data responsibly

---

## 📞 Next Steps

### When Analysis Completes:
1. ✅ Review individual patient reports
2. ✅ Analyze cohort summary statistics
3. ✅ Compare to reference populations
4. ✅ Identify any unusual patterns
5. ✅ Consider additional analyses if needed

### Potential Follow-up Analyses:
- Full variant calling across APOE gene
- Extended haplotype analysis
- Functional variant annotation
- Pathway analysis
- Integration with phenotype data

---

## 🎓 Scientific References

1. Farrer et al. (1997). *JAMA*. "Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease"

2. Liu et al. (2013). *Nature Reviews Neurology*. "Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy"

3. Genin et al. (2011). *Molecular Psychiatry*. "APOE and Alzheimer's disease: a major gene with semi-dominant inheritance"

4. Belloy et al. (2019). *JAMA Neurology*. "A quarter century of APOE and Alzheimer's disease"

---

## ✅ Analysis Status

**CURRENT STATUS: IN PROGRESS**

- ✅ Setup complete
- ✅ Pipeline running
- ⏳ Processing samples (2/26)
- ⏳ ~11-16 hours remaining
- ⏳ Results pending

**Check `BATCH_PROGRESS.md` for live updates!**

---

**Last Updated:** 2025-10-26 13:45  
**Pipeline:** Active and processing  
**Expected Results:** Tomorrow morning (2025-10-27)



